home / stock / eyen / eyen quote
Last: | $0.9374 |
---|---|
Change Percent: | -1.07% |
Open: | $0.9248 |
Close: | $0.9374 |
High: | $0.9575 |
Low: | $0.8513 |
Volume: | 956,447 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.9374 | $0.9248 | $0.9374 | $0.9575 | $0.8513 | 956,447 | 05-02-2024 |
$0.915 | $0.76 | $0.915 | $0.92 | $0.721 | 1,739,463 | 05-01-2024 |
$0.751 | $0.73 | $0.751 | $0.8191 | $0.72 | 1,268,088 | 04-30-2024 |
$0.7122 | $0.62 | $0.7122 | $0.7201 | $0.62 | 908,704 | 04-29-2024 |
$0.6282 | $0.7343 | $0.6282 | $0.759 | $0.5964 | 1,605,690 | 04-26-2024 |
$0.7113 | $0.56 | $0.7113 | $0.8175 | $0.5412 | 3,769,831 | 04-25-2024 |
$0.5835 | $0.555 | $0.5835 | $0.5989 | $0.5383 | 768,647 | 04-24-2024 |
$0.5426 | $0.5159 | $0.5426 | $0.55 | $0.51 | 875,878 | 04-23-2024 |
$0.5165 | $0.5549 | $0.5165 | $0.5698 | $0.5115 | 1,149,629 | 04-22-2024 |
$0.5706 | $0.54 | $0.5706 | $0.59 | $0.52 | 1,371,837 | 04-19-2024 |
$0.5309 | $0.54 | $0.5309 | $0.5447 | $0.52 | 575,667 | 04-18-2024 |
$0.5393 | $0.552 | $0.5393 | $0.5649 | $0.53 | 741,111 | 04-17-2024 |
$0.5534 | $0.5652 | $0.5534 | $0.57 | $0.54 | 885,822 | 04-16-2024 |
$0.5497 | $0.531 | $0.5497 | $0.5499 | $0.51 | 1,699,361 | 04-15-2024 |
$0.53 | $0.61 | $0.53 | $0.6241 | $0.522125 | 1,454,357 | 04-12-2024 |
$0.592 | $0.57 | $0.592 | $0.6599 | $0.5648 | 2,631,153 | 04-11-2024 |
$0.5435 | $0.572 | $0.5435 | $0.5906 | $0.501 | 2,256,863 | 04-10-2024 |
$0.6151 | $0.7486 | $0.6151 | $0.7486 | $0.5701 | 4,381,246 | 04-09-2024 |
$0.7299 | $0.91 | $0.7299 | $0.926 | $0.7161 | 2,892,648 | 04-08-2024 |
$0.89 | $0.919 | $0.89 | $0.9578 | $0.88 | 862,729 | 04-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Eyenovia Inc. Company Name:
EYEN Stock Symbol:
NASDAQ Market:
Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalm...
Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and a potential NDA to the FDA in 2025 Continuing to advance commercialization of Mydcombi for mydriasis and preparing to launch clobe...
Company to demonstrate Mydcombi™ and Avenova ® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 5-8, in Boston Will also demonstrate and discuss commercial terms ...